Ronan Kelly, Director of Precision Medicine and Scientific Discovery at Baylor University Medical Center, shared a post on LinkedIn:
“Scientific Milestone at Baylor University Medical Center!!!
We have treated our first non oncologic patient with CAR-T cell therapy for refractory lupus nephritis, extending CAR-T mediated immune reprogramming beyond the walls of our cancer center.
This case highlights the translational potential of targeted cellular therapy in severe autoimmune disease and the multidisciplinary team we have built in Dallas for the safe delivery of these personalized therapeutics across Internal Medicine.
With a large portfolio of non oncologic CAR-T trials due to open in the next few months combined with our significant experience across both solid and hematologic malignancies we are poised to become a leader in this new era as cell-based platforms expand into immune-mediated disease.”
More posts featuring Ronan Kelly.